Inkocell Therapeutics

Developing the next generation of cell-based therapies.

Different stresses, such as cancer treatment, trigger cardiac fibrosis, leading to heart failure and death. In the US, there are 18M cancer survivors, and 10% of them will develop cardiac fibrosis because of their treatment.

We have developed a patented cell-based therapy that recognizes and eliminates the driver of the disease; our preclinical studies show recovery of heart function following treatment.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

08.09.2025

Inkocell Therapeutics secures CHF 150,000 from Venture Kick to advance next-generation Natural Killer (NK) cell therapies (venturekick.ch)

11.04.2025

Tech innovators of tomorrow face off at Startup Champions Seed Night 2025 (venturelab.swiss)

No milestones

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (150'000) 2025

Website